Viewing nowCombinationEmpagliflozin and Metformin Sustained Release Tablet 12.5/1000 mg (Empagliflozin, Metformin)
Empagliflozin 12.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Dong-A ST Co., Ltd.

MFDS item code 202501721 · Approved 2025.07.09 · Insurance code 642507880
Improvement of glycemic control in adults with type 2 diabetes mellitus
This medication is administered to assist in achieving blood sugar control in adults with type 2 diabetes, in conjunction with dietary management and physical exercise. It is particularly used in patients whose blood sugar levels are not adequately controlled, and in cases of cardiovascular disease, it should be prescribed based on expert guidance. This medication improves blood sugar regulation and positively affects health management in patients with type 2 diabetes.
The dose of this drug for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25mg and metformin hydrochloride extended-release 2000 mg. This drug should be taken once daily with the evening meal to reduce gastrointestinal adverse reactions caused by metformin. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. Patients taking this drug 10/1000 mg extended-release tablets or 25/1000 mg extended-release tablets should take 1 tablet once daily. Patients taking this drug 5/1000 mg extended-release tablets or 12.5/1000 mg extended-release tablets should take 2 tablets at the same time once daily. To maintain the extended-release properties, this drug should be swallowed whole and not split, crushed, ground, or chewed. For patients whose blood glucose is not adequately controlled with metformin alone or in combination with other drugs such as insulin, the recommended initial total daily dose when taking this drug is empagliflozin 10 mg and the patient's current metformin dose. If empagliflozin 10 mg is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg. Patients switching from combination therapy with empagliflozin and metformin to this drug should receive their current doses of empagliflozin and metformin. When switching from immediate-release metformin to an extended-release formulation, glycemic control should be closely monitored and dosage adjustments made as appropriate. When this drug is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia. No dosage adjustment of this drug is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60 mL/min/1.73m2] who tolerate treatment well and have no other conditions that may increase the risk of lactic acidosis, this drug may be used with adjustment of the metformin hydrochloride dose as follows: - Since the starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily, treatment should not be initiated with this drug. The maximum daily dose of metformin hydrochloride is 1000 mg. If creatinine clearance (CrCl) decreases to <45 ml/min or estimated glomerular filtration rate (eGFR) decreases to <45 ml/min/1.73m2, this drug should be discontinued immediately. For patients aged 75 years and older, renal function and the risk of volume depletion should be considered.
This medication is used for the treatment of diabetes, with primary ingredients being Empagliflozin and Metformin. It may occasionally cause a serious side effect called lactic acidosis, which can be life-threatening, so caution is advised. Additionally, when used with insulin or sulfonylureas, there is a risk of hypoglycemia, so care should be taken. This medication should not be administered to certain patients, such as those with severe renal impairment, acute infections, heart diseases, type 1 diabetes patients, or pregnant women. Before and after examinations using iodine contrast agents, this medication should be temporarily discontinued and renal function should be assessed before resuming. Patients with mild renal impairment, elderly patients, or those at risk of fluid loss should be especially cautious when administering this medication and should regularly monitor renal function. This medication may cause side effects in some patients, such as urinary tract infections, genital infections, and increased urination, so patients should consult healthcare providers if symptoms occur. Due to the presence of Metformin, gastrointestinal disturbances may arise, and vitamin B12 levels may decrease, so it is advisable to check vitamin B12 levels during long-term usage. Excessive alcohol consumption should be avoided during treatment, as it may increase the risk of lactic acidosis. Tablets should be swallowed whole and not crushed or chewed, and dosage adjustments and regular testing may be required for the elderly or those with impaired renal function. Patients should inform their healthcare provider immediately if they experience fever, genital pain, rash, severe gastrointestinal symptoms, or symptoms of hypoglycemia while taking this medication. In cases of surgery or serious illness, patients may need to discuss with their healthcare provider whether to temporarily discontinue this medication. This medication may interact with other drugs, so it is important to inform the healthcare provider of any other medications being taken.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to avoid exposure to air or moisture. The storage temperature should be maintained between 1 and 30 degrees Celsius at room temperature.
Brown, oval-shaped, bilayered sustained-release film-coated tablet
30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationEmpagliflozin 12.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Dong-A ST Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 12.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 12.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 12.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.